SOLRIAMFETOL FOR THE TREATMENT OF EXCESSIVE Drowsiness DURING THE DAYTIME
DK3630072T3Active Publication Date: 2026-08-31AXSOME MALTA LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DK2018810236T
- Authority / Receiving Office
- DK · DK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-06-01
- Filing Date
- 2018-06-01
- Publication Date
- 2026-08-31
- Estimated Expiration
- 2038-06-01
AI Technical Summary
Technical Problem
Existing treatments for excessive daytime sleepiness, such as those for obstructive sleep apnea and narcolepsy, fail to achieve normal levels of wakefulness as measured by the Epworth Sleepiness Scale (ESS) and Maintenance of Wakefulness Test (MWT).
Method used
Administering (R)-2-amino-3-phenylpropyl carbamate (APC) or its pharmaceutically acceptable salts in specific amounts to decrease ESS scores to 10 points or less and increase MWT by at least 10 minutes.
Benefits of technology
APC effectively reduces ESS scores to normal levels and enhances MWT performance, demonstrating significant improvement in wakefulness.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.